行情

HCM

HCM

HUTCHMED (China) Limited
NASDAQ

实时行情|Nasdaq Last Sale

37.54
-0.87
-2.27%
盘后: 37.40 -0.14 -0.37% 19:47 09/16 EDT
开盘
37.94
昨收
38.41
最高
38.08
最低
37.38
成交量
38.11万
成交额
--
52周最高
43.94
52周最低
23.67
市值
64.90亿
市盈率(TTM)
-416.6482
分时
5日
1月
3月
1年
5年
美股前瞻 | 三大股指期货齐涨，中国铝业(ACH.US)涨超7%
美股前瞻 | 三大股指期货齐涨，中国铝业(ACH.US)涨超7%
智通财经 · 3天前
BRIEF-Hutchmed (China) Says NMPA Granted Breakthrough Therapy Designation To Amdizalisib
reuters.com · 3天前
HUTCHMED 的淋巴瘤候选药物在中国获得突破性标签
Benzinga · 3天前
和黄医药(HCM.US)盘前涨超3%
和黄医药(HCM.US)盘前涨超3%
格隆汇 · 3天前
HUTCHMED Amdizalisib (HMPL-689) 治疗复发或难治性滤泡淋巴瘤在中国获得突破性疗法认定
HONG KONG and SHANGHAI, China and FLORHAM PARK, N,J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administrati...
GlobeNewswire · 3天前
Hutchmed 的淋巴瘤候选药物在中国获得突破性疗法认定
MT Newswires · 3天前
HUTCHMED 和阿斯利康在中国启动 ORPATHYS®和 TAGRISSO®联合作为一线治疗某些肺癌患者的 SANOVO III 期试验
— Follows important findings from the SAVANNAH study of this combination in lung cancer patients whose tumors harbor mutations or aberrations of EGFR and MET —HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (C...
GlobeNewswire · 09/08 10:30
阿斯利康和 Hutchmed 开始对肺癌联合治疗候选药物进行后期研究
MT Newswires · 09/08 07:43
更多
财务预测
实际值（美元）
预测值（美元）
利润表更多
净利润（美元）
同比（%）
资产负债表更多
总资产（美元）
总负债（美元）
资产负债率（%）
现金流表更多
经营现金流（美元）
同比（%）
了解HCM最新的财务预测，通过HCM每股收益，每股净资产，每股现金流等数据分析HUTCHMED (China) Limited近期的经营情况，然后做出明智的投资选择。
分析师评级

10位分析师的综合评级

买入

免责声明：分析师观点仅供投资者决策参考，不构成任何买卖投资建议。

目标价格预测
分析师预测HCM价格均价为47.39，最高价位54.76，最低价为36.20。
EPS
机构持股
总机构数: 177
机构持股: 5,385.18万
持股比例: 31.15%
总股本: 1.73亿
类型机构数股数
增持
57
431.21万
建仓
23
98.28万
减持
39
465.34万
平仓
12
74.84万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
-0.24%
制药与医学研究
+0.11%
高管信息
Chairman/Director
Simon To
Chief Executive Officer/Executive Director/IR Contact Officer
Christian Hogg
Chief Financial Officer/Executive Director
Chig Fung Cheng
Executive Director
Weiguo Su
Secretary/Non-Executive Director
Edith Shih
Non-Executive Director
Dan Eldar
Non-Executive Independent Director
Paul Carter
Non-Executive Independent Director
Karen Ferrante
Non-Executive Independent Director
Graeme Jack
Non-Executive Independent Director
Shu Kam Mok
暂无数据
  • 全部
  • 财务报告
  • 内部人交易
HCM 简况
HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.

微牛提供HUTCHMED (China) Ltd(NASDAQ-HCM)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的HCM股票新闻，以帮助您做出投资决策。

模拟交易：模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易HCM股票基本功能。